BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30688659)

  • 1. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.
    Wang W; Shen T; Dong B; Creighton CJ; Meng Y; Zhou W; Shi Q; Zhou H; Zhang Y; Moore DD; Yang F
    J Clin Invest; 2019 Mar; 129(3):1015-1029. PubMed ID: 30688659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
    Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.
    Wang W; Han D; Cai Q; Shen T; Dong B; Lewis MT; Wang R; Meng Y; Zhou W; Yi P; Creighton CJ; Moore DD; Yang F
    Nat Commun; 2022 Jan; 13(1):245. PubMed ID: 35017531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT/mTOR pathway.
    Ren J; Zheng S; Zhang L; Liu J; Cao H; Wu S; Xu Y; Sun J
    Cancer Med; 2023 May; 12(10):11624-11640. PubMed ID: 36999945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
    Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway.
    Zhou XM; Sun R; Luo DH; Sun J; Zhang MY; Wang MH; Yang Y; Wang HY; Mai SJ
    Oncotarget; 2016 Mar; 7(12):13634-50. PubMed ID: 26872369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.
    Cipriano R; Miskimen KL; Bryson BL; Foy CR; Bartel CA; Jackson MW
    Oncotarget; 2013 May; 4(5):729-38. PubMed ID: 23676467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
    Zhang Z; Zhu J; Huang Y; Li W; Cheng H
    Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
    Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy.
    Han D; Wang W; Jeon JH; Shen T; Huang X; Yi P; Dong B; Yang F
    PLoS Biol; 2023 Aug; 21(8):e3002227. PubMed ID: 37531320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
    Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY
    Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.